



**T R A N S F O R M**  
p h a r m a c e u t i c a l s , i n c .

## **TRANSFORM PHARMACEUTICALS TO PRESENT AT UBS GLOBAL LIFE SCIENCES CONFERENCE**

**Lexington, MA, September 28, 2004** – TransForm Pharmaceuticals, Inc. today announced that Paul D. Goldenheim, M.D., President, will be presenting at the UBS Global Life Sciences Conference in New York City on Thursday, September 30, 2004.

Dr. Goldenheim will present TransForm's business strategy and key accomplishments at the following time and location:

Event:	<b>UBS Global Life Sciences Conference</b>
Date:	Thursday, September 30, 2004
Time:	1:30 pm (EST)
Location:	The Grand Hyatt Hotel, New York City
Audio:	<a href="http://www.ibb.ubs.com">www.ibb.ubs.com</a>

The public is welcome to listen to the presentation through a UBS audio webcast. To do so, please visit [www.ibb.ubs.com](http://www.ibb.ubs.com) and click on Conferences. Follow the link for live audio under the Global Life Sciences Conference heading. The Presentation will be available live and by replay.

### **About TransForm**

TransForm Pharmaceuticals is an emerging pharmaceutical company with distinctive proprietary technology to “transform” drugs for partners and our own proprietary product pipeline. We have demonstrated that significant clinical and commercial value can be harnessed by optimizing the form and formulation of drugs both in development and those on the market. By understanding the value that physical-chemical properties play in developing the best drug possible, TransForm has created novel proprietary technologies that integrate physical chemistry and materials science with high-throughput parallel optimization technology. As a leader in the field of form and formulation sciences, TransForm has revolutionized the industry's approach to drug development. Our capabilities are broadly applicable

to pharmaceutical products across the entire development and commercialization value chain – from early development to late stage lifecycle management.

We have partnered our expertise with several large pharmaceutical companies including Alza, Lilly, Johnson and Johnson, Abbott and Roche to enable or enhance their drug candidates. In research and development, TransForm works with its partners to help them enable challenging development candidates as well as to assist them in making more effective candidate selection decisions which result in reduced attrition rates, development time and cost. For later stage and marketed products, TransForm works with its partners to enhance the commercial value of these products by rapidly discovering novel forms and/or formulations that improve bioavailability, broaden intellectual property protection, and enable new indications. TransForm is leveraging its capabilities into medicated devices and biologics. In addition to several successful partnered programs, TransForm is applying its novel capabilities to developing a proprietary product pipeline to achieve its mission of becoming an emerging pharmaceutical company.

More information on TransForm can be found at: [www.transformpharma.com](http://www.transformpharma.com).

For more information, please contact:  
Barbara Carter  
TransForm Pharmaceuticals, Inc.  
781/674-7834

###